Mayo Clinic Consensus Statement for the Use of Bisphosphonates in Multiple Myeloma

Lacy, Martha Q.; Dispenzieri, Angela; Gertz, Morie A.; Greipp, Philip R.; Gollbach, Kimberly L.; Hayman, Suzanne R.; Kumar, Shaji; Lust, John A.; Rajkumar, S. Vincent; Russell, Stephen J.; Witzig, Thomas E.; Zeldenrust, Steven R.; Dingli, David; Bergsage, P. Lief; Fonseca, Rafael; Reeder, Craig B.; Stewart, A. Keith; Roy, Vivek; Dalton, Robert J.; Carr, Alan B.
August 2006
Mayo Clinic Proceedings;Aug2006, Vol. 81 Issue 8, p1047
Academic Journal
Bisphosphonates are effective in the prevention and treatment of bone disease in multiple myeloma (MM). Osteonecrosis of the jaw is increasingly recognized as a serious complication of long-term bisphosphonate therapy. issues such as the choice of bisphosphonate and duration of therapy have become the subject of intense debate given patient safety concerns. We reviewed available data concerning the use of bisphosphonates in MM. Guidelines for the use of bisphosphonates in MM were developed by a multidisciplinary panel consisting of hematologists, dental specialists, and nurses specializing in the treatment of MM. We conclude that intravenous pamidronate and intravenous zoledronic acid are equally effective and superior to placebo in reducing skeletal complications. Pamidronate is favored over zoledronic acid until more data are available on the risk of complications (osteonecrosis of the Jaw). We recommend discontinuing bisphosphonates after 2 years of therapy for patients who achieve complete response and/or plateau phase. For patients whose disease is active, who have not achieved a response, or who have threatening bone disease beyond 2 years, therapy can be decreased to every 3 months. These guidelines were developed in the interest of patient safety and will be reexamined as new data emerge regarding risks and benefits.


Related Articles

  • Pamidronic acid/zoledronic acid.  // Reactions Weekly;8/21/2010, Issue 1315, p38 

    The article describes the cases of five patients who developed osteonecrosis of the jaw (ONJ) while receiving biphosphonate treatment, using either zoledronic acid or pamidronic acid. One patient, a 56-year-old woman with a history of metastatic breast cancer, presented with right submandibular...

  • The Role of Bisphosphonates in Multiple Myeloma: Mechanisms, Side Effects, and the Future. Pozzi, Samantha; Raje, Noopur // Oncologist;May2011, Vol. 16 Issue 5, p651 

    Zoledronic acid and pamidronate are two potent anti-catabolic nitrogen-containing bisphosphonates (BPs) used extensively in diseases with high bone turnover such as multiple myeloma (MM). In this review we focus on their biology and their current and future use in MM, and highlight some of the...

  • Multiple myeloma in bisphosphonate-affected jaws — a diagnostic challenge: Case report. Katkar, Rujuta A.; Katz, Joseph; Moreb, Jan S.; Nair, Madhu K.; Odont, Lic // Quintessence International;Jul2014, Vol. 45 Issue 7, p613 

    Objective: To discuss the challenges in diagnosis and appropriate management of critical underlying pathoses if a patient presents with signs and symptoms indicative of different conditions that may coexist. Summary: This case features clinical and radiographic challenges in reaching a diagnosis...

  • Different theories on pathogenesis of bisphosphonate-related osteonecrosis of the jaw - A review. Dembowska, Elżbieta; Samulak-Zielińska, Renata; Sporniak-Tutak, Katarzyna // HealthMed;2014, Vol. 8 Issue 1, p140 

    Bisphosphonates (BPs) arc used to manage osteoporosis, Paget's disease, multiple myeloma, bone cancer and metastases, hypercalcemia of malignancy, fibrous dysplasia and chronic osteomyelitis. BPs reduce pain, pathological fractures, the size of osteolytic lesions and limit metastasis in certain...

  • Ostéonécrose des maxillaires : quand l'ancien traitement avec bisphosphonates est méconnu. Renoux, Marion; Folliguet, Marysette; Nguyen, Thông; Radoï, Loredana // Médecine Buccale Chirurgie Buccale;2014, Vol. 20 Issue 3, p177 

    Introduction: Older people have multiple morbidities and are polymedicated. The medicines are prescribed by several doctors who are unaware of each other, hence the increased risk of adverse effects. Observation: We report the case of an institutionalized 91-year-old female patient. Following a...

  • Osteonecrosis of the jaw associated with antiresorptives: more evidence on the role of infection. Pazianas, Michael // IBMS BoneKEy;Nov2013, Vol. 10 Issue 11, p441 

    The author comments on the study conducted by S. Kalyan and colleagues which examines the role of infection in the initiation of osteonecrosis of the jaw (ONJ) associated with antiresorptives. He says that the significance of this study on the unaffected part of monocytes in patients treated...

  • Pamidronic acid/zoledronic acid.  // Reactions Weekly;10/7/2006, Issue 1122, p18 

    The article presents case reports of two patients who developed jaw osteonecrosis during treatment with pamidronic acid or zoledronic acid. A man received zoledronic acid as treatment for his multiple myeloma. On the other hand, a woman with osteoporosis received IV pamidronic acid. She...

  • Bisphosphonate-related osteonecrosis of the jaw in a multiple myeloma patient: A case report with characteristic radiographic features. Byung-Do Lee; Moo-Rim Park; Kyung-Hwan Kwon // Imaging Science in Dentistry;2015, Vol. 45 Issue 3, p199 

    A 59-year-old male who had suffered from multiple myeloma for nine years and had been administered bisphosphonates for seven years visited a dental hospital for pain relief due to extensive caries in his left maxillary molars. The molars were extracted, leaving an exposed wound for three months....

  • A different schedule of zoledronic acid can reduce the risk of the osteonecrosis of the jaw in patients with multiple myeloma. Corso, A; Varettoni, M; Zappasodi, P; Klersy, C; Mangiacavalli, S; Pica, G; Lazzarino, M // Leukemia (08876924);Jul2007, Vol. 21 Issue 7, p1545 

    Osteonecrosis of the jaw (ONJ) is a reported complication of bisphosphonate use. The incidence ranges between 6 and 13% and seems to be higher in people treated with zoledronic acid (ZA) than with pamidronate. We retrospectively evaluated the incidences of ONJ and skeletal-related events (SRE)...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics